 |
11 Diseases |  |
1 Trial |
|
1 Trial |  |
105 News |  |
| «12 |
- glembatumumab vedotin (CDX-011) / Celldex
Enrollment open: AOST1521: Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Feb 21, 2016
P2, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting
- glembatumumab vedotin (CDX-011) / Celldex
Trial initiation date: AOST1521: Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Feb 16, 2016
P2, N=38, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Aug 2015 --> Apr 2016
- glembatumumab vedotin (CDX-011) / Celldex
Enrollment open, IO biomarker, Metastases: Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma (clinicaltrials.gov) - Oct 2, 2015
P2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- glembatumumab vedotin (CDX-011) / Celldex
Trial initiation date, IO biomarker, Metastases: Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma (clinicaltrials.gov) - Jul 21, 2015
P2, N=34, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Jul 2015 --> Nov 2015
- glembatumumab vedotin (CDX-011) / Celldex
New P2 trial: AOST1521: Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Jul 2, 2015
P2, N=38, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- glembatumumab vedotin (CDX-011) / Celldex
New P2 trial, IO biomarker, Metastases: Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma (clinicaltrials.gov) - Feb 18, 2015
P2, N=32, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||| glembatumumab vedotin (CDX-011) / Celldex
Enrollment open, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma (clinicaltrials.gov) - Dec 27, 2014
P2, N=60, Recruiting, Sponsor: Celldex Therapeutics
Initiation date: Jul 2015 --> Nov 2015 Not yet recruiting --> Recruiting
- ||||| glembatumumab vedotin (CDX-011) / Celldex
New P2 trial, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma (clinicaltrials.gov) - Nov 28, 2014
P2, N=60, Not yet recruiting, Sponsor: Celldex Therapeutics
- || glembatumumab vedotin (CDX-011) / Celldex
Trial primary completion date, Metastases: METRIC: Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 7, 2014
P2, N=300, Recruiting, Sponsor: Celldex Therapeutics
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Nov 2016
- ||||| glembatumumab vedotin (CDX-011) / Celldex
New P2 trial, Metastases: METRIC: Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 26, 2013
P2, N=300, Recruiting, Sponsor: Celldex Therapeutics
- |||| glembatumumab vedotin (CDX-011) / Celldex
Trial completion, Metastases: EMERGE: A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer (clinicaltrials.gov) - Nov 28, 2012
P2, N=120, Completed, Sponsor: Celldex Therapeutics
Trial primary completion date: Sep 2015 --> Nov 2016 Active, not recruiting --> Completed